Physician profile
Gregory Seltzer
NPI 1194901553
$30,663.83
in general payments reported to CMS, 2019-2025
32 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $632 · 2021: $929 · 2022: $622 · 2023: $1,442 · 2024: $2,866 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $6,357 · Travel and Lodging: $4,984 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,303.60 |
| Food and Beverage | $6,357.15 |
| Travel and Lodging | $4,984.01 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $20,355.16 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $3,802.73 | 2023-2025 | Gi Genius, Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,139.16 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $831.78 | 2019-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $696.58 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $606.77 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $466.34 | 2020-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $404.45 | 2019-2025 | Exalt Model D, General - Biliary Devices, Watchman |
| Regeneron Healthcare Solutions, INC. | $296.85 | 2023-2025 | Dupixent |
| Celgene Corporation | $247.76 | 2021-2024 | Zeposia |
| Genzyme Corporation | $246.75 | 2022-2025 | |
| Pfizer INC. | $193.04 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $175.61 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $168.97 | 2019-2024 | Rebyota, Clenpiq, Cimzia |
| Ambu INC. | $162.11 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $129.21 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $113.29 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $106.32 | 2019-2023 | Injectafer |
| Lilly USA, LLC | $101.60 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $82.66 | 2019-2021 | |
| Braintree Laboratories, INC. | $54.71 | 2019-2025 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $46.60 | 2020-2021 | |
| Madrigal Pharmaceuticals | $39.14 | 2025 | Rezdiffra |
| Organon LLC | $29.18 | 2024 | |
| Evoke Pharma, INC. | $27.37 | 2021 | |
| Redhill Biopharma INC. | $27.03 | 2021 | |
| Intercept Pharmaceuticals, INC. | $26.11 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $22.22 | 2025 | Iqirvo |
| Celltrion USA INC. | $18.34 | 2025 | Vegzelma |
| Ge Healthcare | $16.82 | 2025 | |
| Covidien Lp | $16.21 | 2019 | |
| Shionogi INC | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Seltzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.